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Abstract
Background: The accumulation of mitochondrial DNA (mtDNA) mutations, and the reduction of mtDNA copy
number, both disrupt mitochondrial energetics, and may contribute to aging and age-associated phenotypes.
However, there are few genetic and epidemiological studies on the spectra of blood mtDNA heteroplasmies, and
the distribution of mtDNA copy numbers in different age groups and their impact on age-related phenotypes. In
this work, we used whole-genome sequencing data of isolated peripheral blood mononuclear cells (PBMCs) from
the UK10K project to investigate in parallel mtDNA heteroplasmy and copy number in 1511 women, between 17
and 85 years old, recruited in the TwinsUK cohorts.
Results: We report a high prevalence of pathogenic mtDNA heteroplasmies in this population. We also find an increase
in mtDNA heteroplasmies with age (β = 0.011, P = 5.77e-6), and showed that, on average, individuals aged 70-years or
older had 58.5% more mtDNA heteroplasmies than those under 40-years old. Conversely, mtDNA copy number
decreased by an average of 0.4 copies per year (β = −0.395, P = 0.0097). Multiple regression analyses also showed
that age had independent effects on mtDNA copy number decrease and heteroplasmy accumulation. Finally, mtDNA
copy number was positively associated with serum bicarbonate level (P = 4.46e-5), and inversely correlated with white
blood cell count (P = 0.0006). Moreover, the aggregated heteroplasmy load was associated with blood apolipoprotein
B level (P = 1.33e-5), linking the accumulation of mtDNA mutations to age-related physiological markers.
Conclusions: Our population-based study indicates that both mtDNA quality and quantity are influenced by age. An
open question for the future is whether interventions that would contribute to maintain optimal mtDNA copy number
and prevent the expansion of heteroplasmy could promote healthy aging.
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Background
Mitochondria play a central role in cellular energy
metabolism, as well as in a range of other cellular activities,
such as calcium signaling, iron homeostasis, hormone syn-
thesis, and programmed cell death [1–3]. Mitochondria
differ from all other organelles in animals in having their
own DNA (mitochondrial DNA, mtDNA), which in
humans encodes 37 genes: 22 tRNAs, 2 rRNAs and 13
protein subunits of the electron transport chain and
Complex V/ATP synthase. Although they contribute only
~1% of the mitochondrial proteome, the 13 mtDNA-
encoded proteins are nevertheless essential for mitochon-
drial oxidative phosphorylation and cellular energetics [4].
A single mammalian cell hosts hundreds to thousands of
copies of mtDNA, which are thought to have played a
critical role in the evolution of mammalian genomic com-
plexity [5]. Because of its multi-copy nature, spontaneous
mtDNA mutations often affect only a small proportion of
the cell’s mtDNA, a state termed heteroplasmy. In contrast,
if all mtDNA molecules harbor a specific mutation, it is
said to be in a state of homoplasmy. mtDNA heteroplasmy
is implicated in several human diseases, in which the ratio
of mutated to wild-type mtDNA is critical in determining
whether a specific mutation is deleterious [2, 6, 7]. In
previous studies, we demonstrated that even in healthy
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adults, low-frequency heteroplasmies with high pathogenic
potential were common [8].
In addition to mtDNA mutation burden, the number
of mtDNA molecules per cell, or “mtDNA copy num-
ber”, is also strictly regulated, ensuring that mitochon-
dria can generate appropriate levels of energy and
intracellular signals to maintain normal cellular func-
tions. Altered mtDNA copy number has been shown to
be involved in age-related diseases, including cancer,
neurodegeneration disorders, and diabetes [9–11]. In the
general population, mtDNA copy number measured in
peripheral blood has also been shown to be associated
with a variety of physiological phenotypes, and to be
linked with aging and mortality [12, 13]. For example,
higher mtDNA copy number was linked with better
physical and mental health status in aged populations
[12]. It has been speculated that both mtDNA
heteroplasmy and copy number may contribute to the
aging process, but the effects of mtDNA heteroplasmy
and copy number were only discussed separately, thus
remaining inconclusive in humans [14].
Aging is commonly characterized as a time-dependent
progressive loss of physiological integrity, leading to
impaired function and increased vulnerability to death
[14]. One important factor in aging is the accumulation
of DNA damage over time [15]. mtDNA has been
considered a major target of aging-associated mutation
accumulation, possibly because it experiences higher
oxidative damages, more turnover, and has lower replica-
tion fidelity compared to nuclear DNA (nDNA) [16–18].
Mice carrying elevated mtDNA mutation burden present
premature signs of aging including hair loss, kyphosis,
and premature death (lifespan shortened by up to 50%)
[19, 20]. In human studies, mtDNA heteroplasmy incidence
increases with age [21–23], while lower mtDNA copy num-
ber has been reported in aged populations [12, 24]. Ding
et al. reported an trend of increased heteroplasmies and
decreased mtDNA copy number with age in their
study population [25]. However, previous studies were
limited in one or more ways: i) limited power in
detecting low-to-medium frequency heteroplasmies in
blood due to low sequencing depth; ii) relatively small
sample sizes, limiting statistical power; iii) small age
range; iv) whole blood as the source of DNA, which
contains several sources of contaminants for mtDNA
analysis; and/or v) assessing either mtDNA mutation
or copy number, but not both in the same biological
samples. Thus, it is largely unknown whether the impacts
of age on mtDNA mutation burden and on copy number
are independent from each other.
Whole genome sequencing (WGS) data allows us to
study mtDNA heteroplasmy and copy number simultan-
eously. Previous large-scale studies of mtDNA hetero-
plasmy or copy number mostly used sequencing data of
total genomic DNA extracted from transformed cell
lines or whole blood. It is possible that during cell line
transformation, both mtDNA heteroplasmy and copy
number could undergo marked changes [26]. Moreover,
estimating mtDNA copy number from WGS data relies
on the ratio of sequencing reads for the mitochondrial
and nuclear genomes extracted from the biological
samples. There are numerous factors in the whole blood
that can bias the estimation of mtDNA copy number.
For example, platelets have high mtDNA content, but
lack nuclear DNA; mtDNA from platelets therefore
artificially raises the estimated mtDNA copy number
from the whole blood [27, 28]. In the current study, we
focused our analysis on WGS data of isolated platelet-
free peripheral blood mononuclear cells (PBMCs) DNA
obtained from the UK10K project TwinsUK cohort,
which includes individuals ranging from 17 to 85 years
of age [29]. The TwinsUK is a cohort with WGS data for
more than 1500 generally healthy female individuals
with phenotypic data. The resulting mtDNA-phenotypic
dataset is one of the largest available in a general human
population for analysis on the relationship between age
and mtDNA heteroplasmy and copy number. Our
analyses reveal that these two mtDNA properties are
significantly correlated with age, and that these age
effects were independent. Our results further indicate
that mtDNA copy number and heteroplasmy load were
significantly associated with age-related physiological
parameters in this population, suggesting potential path-
ways by which age-related mtDNA alterations may
impact the aging process.
Methods
Data access permission
Data used in this study was obtained from UK10K
project, “UK10K Data Access Agreement” was approved
by UK10K Data Access Officer.
mtDNA variation identification and haplogroup
assignment
Whole genome sequencing and subsequent read map-
ping of the TwinsUK cohorts were accomplished by the
UK10K project [29]. Briefly, DNA (1–3 μg) extracted
from PBMCs was sheared to 100–1000 bp, and sheared
DNA was sent to Illumina paired-end DNA library prep-
aration. After size selection (300–500 bp insert size), the
DNA library was sequenced by the Illumina HiSeq plat-
form with paired-end read lengths of 100 bp. Sequencing
reads mapping to the mitochondrial genome were
extracted from indexed bam files to identify hetero-
plasmy in each individual. Retrieved reads were
re-mapped to the combined human genome, hg19 for the
nuclear genome and the revised Cambridge Reference
Sequence (rCRS) for the mitochondrial genome, using
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bowtie2 [30]. Read pairs with proper orientation and less
than 5 mismatches were retained from the mapping
results. The nuclear genome contains some regions with
high similarity to part of the mtDNA (nuclear mitochon-
drial DNA, abbreviated as NUMTs). To minimize the
effect of NUMTs for heteroplasmy calling, we further
required the retained reads to be uniquely mapped to the
mitochondrial genome. Filtered reads were further
processed following the GATK best practice workflow,
including Mark duplicates (duplicated reads were re-
moved), Indel realignment, and Base quality score recali-
bration steps. Homoplasmies were identified using GATK
HaplotypeCaller and GenotypeGVCFs [31]. Haplogroups
were assigned using homoplasmic variants identified from
each sample by HaploGrep2 [32]. To identify hetero-
plasmy, sequencing data for each position of the mito-
chondrial genome was extracted by Samtools mpileup
[33], and bases were further filtered by sequencing quality
(> = 20). Heteroplasmy was then identified with the
following criteria: 1) Sequencing coverage >200. 2) Minor
allele frequency > = 2%. 3) Minor allele must be observed
at least twice from each strand.
Potential cross-sample contamination inspection
Potential cross-sample contamination was assessed in
the UK10K project’s original data processing by
VerifyBamID [34] and “fraction skewed hets” [29]. Potential
contaminated samples were already removed from the
dataset. However, to be more conservative, we further
tested contamination using mtDNA sequencing data,
which has better sensitivity than nuclear DNA variants
based methods. We evaluated potential contamination by 2
criteria 1) if a sample had extremely high heteroplasmy
number (Q3 + 1.5IQR rule); by this criterion, samples hav-
ing more than 8 heteroplasmies were suspected to be con-
taminated. 2) We constructed two consensus mtDNA
sequences for each sample, one covering the major alleles
at heteroplasmic sites, the other covering minor alleles. A
sample was suspected to be contaminated if these two con-
sensus sequences belonged to different haplogroups. If a
sample met both criteria, we would recognize it as contam-
ination and remove it from further analysis.
Annotation of mtDNA variants
Heteroplasmy and homoplasmy were annotated by
customized scripts. Pathogenic potential of variants was
predicted using Combined Annotation-Dependent
Depletion (CADD) score (version 1.3) [35]. The CADD
score integrated many diverse annotations of variants,
including functionality, pathogenicity, experimentally
measured effects etc., into a single score, which has been
shown to have better performance than other predictive
methods such as Grantham, SIFT and PolyPhen. As
recommended, a scaled CADD score of 15 was used to
define the pathogenic mutations. To avoid the bias of an
arbitrary cutoff, a series of cutoffs from 12 to 22 were
also applied to evaluate the variants’ pathogenicity. The
disease associated mtDNA mutations were obtained
from the MITOMAP database [36].
mtDNA copy number estimation
Whole genome sequencing data of the study population
were retrieved from the UK10K project [29]. To estimate
mtDNA copy number, we further filtered mapped reads
by the following criteria: 1) Mapping quality >20. 2)
Reads were not PCR duplicates. 3) Mismatches <5. We
proceeded with qualified reads for subsequent calcula-
tion. Sequencing coverage of each site in the reference
genome was calculated by the Samtools mpileup func-
tion [33]. The average sequencing coverage was then
calculated for each autosomal DNA and mtDNA locus.
mtDNA copy number of each individual was further
estimated based on Eq. 1 and Eq. 2. It has been shown
that NUMTs have a negligible impact on mtDNA copy












Association testing for mtDNA copy number and
heteroplasmy
Linear regression was carried out to test the association
of mtDNA heteroplasmy with age, as well as copy
number with age separately. To conveniently test the in-
dependence of the effects of age on mtDNA heteroplasmy
and copy number, we performed a linear regression using
age as response variable, and mtDNA copy number and
heteroplasmy number as independent variables in the
basic model (Eq. 3). WBC count and platelet count were
reported to affect mtDNA copy number [24], thus these
two factors were also included as covariates in the regres-
sion model for further analysis (Eq. 4). Down sampling
was carried out by randomly sampling 0.06 million
mtDNA reads from each individual and identifying
heteroplasmy following the same criteria. The association
of mtDNA copy number with mtDNA heteroplasmy
number was assessed by linear regression, with age and
mean nuclear coverage included as covariates. The influ-
ence of mtDNA variants (heteroplasmy, homoplasmy,
haplogroup) on mtDNA copy number was tested by linear
regression, with age and mean nuclear coverage included
as covariates. For homoplasmy, variants present in more
than 1% individuals were tested. The significance level was
adjusted for multiple testing. Homoplasmic variants with
P value <2.69e-4 were considered to be significant.
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AgeemtDNAheteroplasmy number þmtDNA copy number
ð3Þ
AgeemtDNAheteroplasmy number þmtDNA copy number
þWBC count þ Platelet count
ð4Þ
Phenotypic associations of mtDNA copy number and
heteroplasmy
We assessed the associations of 32 phenotypes directly
measured from blood samples with mtDNA copy num-
ber and heteroplasmy number. The details of phenotypic
data measurements can be found from the UK10K pro-
ject [29]. Linear regression models were applied to test
for associations, and age was included as a covariate to
adjust for its effects on these phenotypes. Significance
levels were adjusted by Bonferroni correction. Effects
were considered as significant if P value <0.0016.
Mitochondrial heteroplasmy load and SKAT test
The Sequence Kernel Association Test (SKAT) has been
shown to have high statistical power under a variety of
conditions [38]. We used it to test the association of
mtDNA heteroplasmic mutation load with different phe-
notypes. To do the association test, we first constructed
a genotype matrix containing mtDNA heteroplasmy
information. Assuming that we have mtDNA sequences
for n individuals, and there are, in total, m unique
heteroplasmic variants among those individuals, then the
genotype matrix could be constructed an n x m matrix X,
where the entry aij in X represents the minor allele
frequency of individual i at heteroplasmic site j. To calcu-
late aij, the number of all possible bases (A, T, G, C) with
sequencing quality >20 were counted for individual i at
site j. If the minor allele count exceeded 5, minor allele
frequency would be calculated by dividing the minor allele
count by total coverage at the given site, otherwise aij
would be set to 0. We also constructed another genotype
matrix X’, whose entries were either 0 or 1. This matrix
will only consider whether a given site is heteroplasmic
(as 1) or not (as 0), regardless of the minor allele
frequency. Notably, the genotype matrices only contained
the non-polymorphic heteroplasmies. After constructing
the genotype matrix, a linear regression model can be
considered (Eq. 5):
Y ¼ α0 þ Cαþ Xβ ð5Þ
Where C is the covariates matrix, in which we
included age, mtDNA copy number, and the top 2 PCs
from principle component analysis of population struc-
ture. Phenotypes were log transformed to achieve
normal distributed residuals. The CADD score of each
heteroplasmic variant was used as the weights. This
weighting scheme could upweight heteroplasmic variates
which are predicted to be more deleterious. The tests
were performed using the R package SKAT [38].
Results
Mitochondrial heteroplasmy is prevalent in UK10K
TwinsUK cohort
The UK10K-cohorts arm [29] provided WGS data for
healthy individuals from two British cohorts of European
ancestry, namely the Avon Longitudinal Study of Parents
and Children (ALSPAC) [39] and TwinsUK [40]. How-
ever, the genomic DNA used in these two cohorts was
different. In ALSPAC, DNA was extracted from lympho-
blastoid cell lines established in vitro, while DNA in
TwinsUK was extracted from isolated PBMCs. We com-
pared the mtDNA copy number distribution between
the two cohorts and observed a dramatically higher
mtDNA copy number in cell line DNA (Additional file 1:
Figure S1). The higher mtDNA copy number in the cell
line compared to PBMCs is likely attributable to the
difference in biological material, rather than a genuine
cohort difference. Therefore, in the current study, we
only focused on individuals from the TwinsUK cohort
for which PBMC DNA was available. In the UK10K
project’s original study design, in order to increase
the genetic diversity and decrease the sequencing
costs, only one individual from each of the twin pairs
recruited was sequenced at the whole-genome level.
After excluding 73 individuals with potential cross-
sample contamination, we retained 1511 individuals
for further analysis. The average age of these studied
individuals was 55.5 years (SD = 12.8 years), ranging
from 17.3 years to 84.5 years.
The average sequencing coverage of the mitochondrial
genome in these individuals was ~568X, allowing us to
reliably identify mtDNA heteroplasmy at 2% minor allele
frequency (MAF) cutoff. After applying a series of
criteria to filter out low-quality heteroplasmies, we iden-
tified 1348 mtDNA heteroplasmies in 1511 individuals;
the detailed heteroplasmy information is summarized in
Additional file 2: Table S1. 794 (52.5%) individuals
harbored at least one heteroplasmy in their mitochon-
drial genome (Fig. 1a). Most heteroplasmies presented at
low-to-medium frequency (62.7% of heteroplasmies have
MAF < 5%, Fig. 1b). The gene-length normalized distri-
bution of heteroplasmy frequency among mtDNA loci is
shown in Fig. 1c. The distribution of homoplasmy
frequency was also plotted. Heteroplasmies were
observed over the entire mitochondrial genome. One
exception was the control region, also known as the
“hypervariable region” [41], which harbored the
highest occurrence (normalized by region length) of
both homoplasmic and heteroplasmic variants. Other
regions were relatively homogenous with a few
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exceptions (Additional file 1: Table S2): tRNA-Thr,
which is positioned immediately upstream from the
control region, had significantly higher frequencies than
other tRNA genes in both heteroplasmy and homoplasmy
(P = 0.00015 and 0.00297, respectively, Chi-squared outlier
test). Interestingly, we observed that ND5 had a moderate
occurrence frequency in homoplasmy, but significant
higher frequency in heteroplasmy than other protein
coding genes (P = 0.00494, Chi-squared outlier test).
Mitochondrial heteroplasmy has high pathogenic
potential
Among the 1348 heteroplasmies, 192 (14.2%) were
previously reported to be associated with diseases. 11.4% of
individuals harboring at least one of these diseases-associated
heteroplasmies. To further investigate the pathogenicity of
the heteroplasmies, combined annotation dependent de-
pletion (CADD) scores [35] were used to predict the po-
tential pathogenicity of nonsynonymous mutations in
heteroplasmy and homoplasmy. We also annotated
CADD scores for disease-associated mutations (retrieved
from MITOMAP [36]) as a comparison. Disease-causing
nonsynonymous mutations had a mean pathogenicity
score of 17.43; in comparison, the mean CADD score of
the 294 unique nonsynonymous heteroplasmic mutations
was 14.32, which was significant higher than the 359 unique
nonsynonymous homoplasmic mutations (10.84. P =
3.967e-7, Welch two sample t-test, Fig. 2a, Additional file 1:
Figure S2). As suggested by the CADD score database,
CADD score > 15 can be used as a cutoff to define muta-
tions with high possibility to be pathogenic [35]. With this
cutoff, the proportion of high pathogenic potential muta-
tions in heteroplasmy was significantly higher than that in
homoplasmy (P = 0.00825, Chi-square test). With the
same criterion, 51.4% of heteroplasmies were high patho-
genic potential while only 34.8% of homoplasmic muta-
tions were high pathogenic potential. To avoid the
potential bias of the arbitrary cutoff, we also applied a
Fig. 1 Distribution of heteroplasmy in UK10K TwinsUK cohort. a Counts of individuals harboring a specific number of heteroplasmies (0–12
heteroplasmies at MAF > 2% cutoff). More than half of individuals (52.5%) carried at least one heteroplasmy in their genome. b Histogram for
MAF of all heteroplasmies. 62.7% of heteroplasmies had MAF < 5% and 20.1% had MAF > 10%. c Normalized occurrence frequency distribution
of heteroplasmies and homoplasmies. The frequency was normalized by the length of the mitochondrial loci. Dark gray, light blue and yellow
bars indicate the genes in three different functional categories: rRNA, Protein coding and tRNA, respectively. The distribution of variants was
relatively homogeneous among coding regions, except for some regions, such as higher frequency in ND5 (heteroplasmy) and tRNA Thr
(heteroplasmy and homoplasmy)
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series of CADD score cutoffs from 12 to 22, and hetero-
plasmy was 1.42 to 1.94 times more likely to be high
pathogenic potential than homoplasmy under different
cutoffs (Additional file 1: Figure S3), consistent with the
notion that more pathogenic mutations are more likely to
be eliminated through purifying selection than less
deleterious ones [8].
To further investigate this hypothesis, we separated
nonsynonymous heteroplasmy into low frequency and
high frequency groups using 10% MAF as a cutoff. The
low frequency heteroplasmy group had significantly
higher CADD scores than the high frequency group
(P = 0.019, Welch two sample t test). Again, to avoid
the potential bias of arbitrary cutoffs, we applied
several MAF frequency cutoffs to separate low and
high frequency groups (from 5% to 9%), and the
difference remained significant until the cutoff was as
low as 6%. To visualize this difference, we plotted the
cumulative distribution of CADD scores for each group.
The distribution of CADD scores for low frequency
heteroplasmies approached that of disease-associated
mutations, whereas the distribution of high frequency
heteroplasmies moved towards that of homoplasmic
mutations (Fig. 2b, Additional file 1: Figure S4).
Mitochondrial heteroplasmy burden increases with age
The mtDNA haplogroup of each individual was identi-
fied using Haplogrep2 [32]. In this population, 48.5%
(733) of the individuals belonged to H haplogroup, and
there were 4 other haplogroups having more than 100
individuals: U (220), K (143), J (135) and T (125). This
distribution is typical for a population of predominantly
European descent. The haplogroups did not significantly
contribute to the heteroplasmy variance (P > 0.05 for
Fig. 2 Pathogenic potential for nonsynonymous heteroplasmies. a The box plot of CADD pathogenic score for disease associated mutations,
nonsynonymous heteroplasmies and nonsynonymous homoplasmies (heteroplasmy and homoplasmy occurring in multiple individuals were
counted only once). Heteroplasmies had significant higher pathogenic scores than homoplasmies (P = 3.967e-7) although still lower than disease
associated mutations (P < 2.2e-16). b The cumulative distribution of CADD pathogenic scores of disease associated mutation, homoplasmy, low
frequency heteroplasmy (MAF 2%–10%) and high frequency heteroplasmy (MAF > 10%). The distribution of low frequency heteroplasmy was
close to disease associated mutations, indicating higher pathogenic potential
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each haplogroup, Additional file 1: Figure S5), and thus
were not considered in subsequent analysis.
mtDNA mutations have been thought to play an
important role in aging. To investigate changes of het-
eroplasmies with age, we first applied linear regression
and found that heteroplasmy number increased with age
(β = 0.011, P = 5.77e-6, linear regression. Additional file 1:
Figure S6). To better describe the changing hetero-
plasmy trend during aging, we further divided the 1511
individuals into five age groups. We observed a gradual
and consistent increase of heteroplasmy number from
the youngest group aged under 40-years to the oldest
group aged over 70-years (Table 1). On average, indi-
viduals over 70-years old had 1.11 heteroplasmies,
significantly higher than individuals under 40-years
old (0.70 heteroplasmy, P = 0.001593, Welch two sam-
ple t test). We also separated heteroplasmy into low-
to-medium MAF (2%–5%) and medium-to-high MAF
(>5%) intervals, and found that this increasing trend
was consistent for heteroplasmy in different MAF
intervals. Individuals under 40-years old had 0.41 het-
eroplasmy with MAF 2%–5% and 0.29 heteroplasmy
with MAF >5%, while individuals over 70-years old
had 0.68 and 0.43, respectively.
Next, we evaluated the spectra of heteroplasmy in
the five age groups. In all groups, heteroplasmy was
predominantly present in protein coding regions,
which was not surprising since protein coding
sequences account for >67% of mtDNA. However, there
was a tendency for the proportion of nonsynonymous het-
eroplasmies to increase with age. 25.9% of heteroplasmies
were nonsynonymous in the under 40-years group, which
increased to 28.6% in the over 70-years group, while
the proportion of synonymous heteroplasmies did not
significantly change (Table 2). Since nonsynonymous
mutations are more likely to cause functional conse-
quences than synonymous ones, this increased nonsy-
nonymous proportion, together with the increased
absolute heteroplasmy number in older individuals,
could suggest that mtDNA integrity, or “quality” dete-
riorates with age.
Age has independent effects on mtDNA heteroplasmy
and copy number
Because mtDNA heteroplasmy level can be affected by
copies of mtDNA in blood, the age-related increase of
heteroplasmy may reflect the consequences of decreased
mtDNA copy number in older individuals [37]. We
therefore investigated whether age acted on mtDNA
heteroplasmy and copy number independently by
incorporating data on heteroplasmy and copy number,
simultaneously, in our analytical models with age. In
normal human cells, there are two fixed copies of the
nuclear genome, and therefore the ratio of average WGS
sequencing coverage for mitochondrial and nuclear
genomes can be used to estimate mtDNA copy num-
ber. Assuming that autosomal and mtDNA are proc-
essed and sequenced with no significant difference,
average sequencing coverage should be proportional to
DNA copy number for autosomal and mtDNA (Eq. 1),
thus mtDNA copy number can be estimated using Eq.
2. By this method, we observed a broad range of
mtDNA copy number among these individuals (Fig. 3a),
from 65 to 573, with mean 169 and median 188. The
distribution of mtDNA copy number was positively
skewed (P < 2.2e-16, D’Agostino’s test), with a coeffi-
cient of skewness of 1.55. Our results showed that
mtDNA copy number and age were negatively corre-
lated (β = −0.395, P = 0.00972, linear regression, Fig. 3b).
For every 10 years, mtDNA copy number decreases
about 4 copies. Similar to mtDNA heteroplasmy,
mtDNA copy number was also not significantly
affected by haplogroups (Additional file 1: Figure S7).
We next asked whether the effects of age on
mtDNA copy number and mtDNA heteroplasmy were
independent from one another. We tested this hy-
pothesis by performing a linear regression between
age and mtDNA copy number/heteroplasmy number
(Eq. 3). In this regression model, both copy number
and heteroplasmy number showed significant associa-
tions with age (Table 3), suggesting that age-related
mtDNA copy number decrease and heteroplasmy
increase are independent.
Table 1 Heteroplasmy number in different age groups
Age Group < 40 40–50 50–60 60–70 > 70
Age Mean 30.12 45.24 55.27 64.28 74.07
Age SD 6.41 2.72 2.92 2.94 3.35
Individual count 166 267 464 447 167
Heteroplasmy counta 0.70; (44.6%) 0.72; (47.2%) 0.89; (55.0%) 0.98; (53.5%) 1.11; (60.0%)
Heteroplasmy count (MAF 2–5%) 0.41; (28.3%) 0.48; (32.2%) 0.56; (36.9%) 0.62; (38.7%) 0.68; (39.5%)
Heteroplasmy count (MAF > 5%) 0.29; (22.9%) 0.24; (20.6%) 0.33; (28.4%) 0.37;(27.7%) 0.43; (32.3%)
anumbers in parentheses indicate the proportion of individuals harboring heteroplasmy with specified MAF cutoffs. An individual can have heteroplasmies in both
MAF groups
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In addition, since DNA was extracted from blood cells,
and WBC count and platelet count were reported to
correlate with age and mtDNA copy number [24], we
further included WBC count and platelet count as
covariates (Eq. 4). These additional adjustments for
possible confounding factors did not qualitatively alter
the associations obtained in the basic model (Table 4).
Additionally, because it was more likely to identify het-
eroplasmies in individuals with high mtDNA sequencing
coverage, as a sanity check, we down sampled mtDNA
sequencing reads in each individual to 0.06 million
mtDNA reads (corresponding to mtDNA sequencing
coverage of ~ 360X) and identified heteroplasmies at 2%
MAF cutoff. The independent effects of age on mtDNA
heteroplasmy and copy number were still significant in
the down-sampled data (Additional file 1: Table S3, S4),
confirming the robustness of this finding across the
whole population.
Mitochondrial DNA copy number is associated with
number of heteroplasmies
We next tested the correlation between mtDNA copy
number and heteroplasmy. Since most heteroplasmies
were unique to only one individual, especially those with
high pathogenic potentials, instead of testing each single
mtDNA heteroplasmy, our analysis was restricted to
test the association between mtDNA copy number
and the total number of heteroplasmies within an
individual. With increasing heteroplasmy number,
mtDNA copy number significantly decreased (Fig. 4.
β = −4.34, P = 0.007, linear regression, adjusted for age
and average nuclear DNA sequencing coverage).
We also tested whether single mtDNA homoplasmic
variants were associated with copy number. We identified
186 unique homoplasmic single nucleotide variants, each
presented in >1% of individuals in this study population.
The associations between mtDNA copy number and these
variants were tested using a linear model including age
and mean nuclear DNA sequence coverage as covariates.
After Bonferroni correction, none of these homoplasmic
variants were significantly associated with mtDNA copy
number (Additional file 1: Figure S8). Ridge et al. previ-
ously reported that 3 mtDNA variants (A9667G, T5277C
and C6489A), belonging to haplogroups T2 and U5A1,
were significantly associated with higher mtDNA copy
number [42]. There were 26 individuals in our dataset
harboring A9667G, but this variant was not associated
with mtDNA copy number in our test (P = 0.5669). The
other two variants were missing or found at a rare
frequency (7 individuals) in our study, and thus were
excluded from further association analysis.
Phenotypic associations of mtDNA copy number and
heteroplasmy load
Age is the most significant risk factor for several
diseases. It is possible that the effects of age on mtDNA
Table 2 Regional distribution of heteroplasmy in different age groups
Control region Intergenic region rRNA tRNA Nonsynonymous Synonymous
<40 18.1% 0.9% 12.9% 5.2% 25.9% 37.1%
40–50 24.9% 0.5% 13.0% 6.2% 25.9% 29.5%
50–60 27.3% 0.5% 9.9% 3.4% 26.8% 32.1%
60–70 22.0% 0.2% 12.0% 2.5% 28.2% 35.0%
>70 16.8% 0.0% 13.5% 4.9% 28.6% 36.2%
Fig. 3 Distribution of mtDNA copy number in the UK10K Twins cohort and its association with age. a mtDNA copy number was estimated using
WGS data by comparing the mean sequencing coverage of mtDNA and nDNA. The distribution of mtDNA copy number was positively skewed,
and most individuals had moderate numbers of mtDNA (mean 169 and median 188). b mtDNA copy number was negatively correlated with age
(β = −0.395, P = 0.00972). Blue line represents the linear regression line. For every 10 years, mtDNA copy number decreases about 4 copies
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copy number and heteroplasmy could mediate these
effects via their effects on physiological variables known to
be perturbed in disease states and with aging. We
examined the associations between 32 phenotypic traits
provided by TwinsUK cohort and mtDNA copy number /
heteroplasmy load (Additional file 3: Table S5). After
correcting for multiple testing, mtDNA copy number was
significantly associated with serum bicarbonate level (P =
4.46e-5, Fig. 5a) and WBC count (P = 0.0006, Fig. 5b).
Bicarbonate is an essential component of the pH
buffering system and is indirectly related to mitochondrial
oxidative reactions. In our analysis, there was a positive
correlation between mtDNA copy number and serum
bicarbonate level, such that, for each increase of 1 SD in
mtDNA copy number (75.8 copies), serum bicarbonate
level increased by 0.102 SD (0.27 mmol/L), indicating a
potential interplay between the buffering system and
mitochondrial activity. Conversely, WBC showed a signifi-
cant negative correlation with mtDNA copy number.
With each increase of 1 SD in mtDNA copy number,
WBC count decreased by 0.116 SD (0.2*109 cell/L). WBC
count is related to inflammation and immune senescence,
so this observation indicated that mtDNA copy number
could be associated with immune function.
Since the majority of the heteroplasmies were present
in <1% of individuals in the samples, our ability to test
their phenotypic associations were limited. Instead of
performing analysis on each single heteroplasmy, we
aggregated the heteroplasmic mutation information across
the entire mitochondrial genome for each individual, and
attempted to test the overall cumulative effects of hetero-
plasmy on different traits. We used the Sequence Kernel
Association Test (SKAT) algorithm, which has been
shown to have high statistical power under a variety of
conditions [38]. Under SKAT default settings, the popula-
tion frequencies of the variants were used as testing
weights, since rare mutations were more susceptible to
being deleterious. Here, because most heteroplasmies
were only found in one person, we used the predicted
pathogenicity of heteroplasmy (CADD scores) as weights.
We tried two different genotype matrices, one taking the
heteroplasmy MAF into account, the other only consider-
ing whether a site was a heteroplasmy or not, regardless
of the MAF. In both cases, after multiple test correction,
we observed that mtDNA heteroplasmy load was signifi-
cantly associated with blood apolipoprotein B (ApoB) level
(P = 1.33e-5 and 3.73e-6, respectively), but not with
other phenotypes. Because ApoB is a component of the
lipid transport system linked to cardiovascular disease
risk [43–46], this suggested a potential link between
mtDNA integrity and physiological lipid regulation.
Discussion
In this study, we first identified mtDNA heteroplasmies in
1511 generally healthy women using PBMC whole gen-
ome sequencing data from the UK10K project TwinsUK
cohort, with an age range from 17 to 85 years of age. With
2% MAF cutoff, we demonstrated that more than half of
the individuals (52.5%) harbor at least one heteroplasmy
in their mitochondrial genome, and on average each indi-
vidual had ~0.9 heteroplasmy. Both the proportion of
individuals harboring heteroplasmy and the average het-
eroplasmy number per person (using the same MAF 2%
cutoff) were lower compared to our previous hetero-
plasmy study using sequencing data from the 1000 gen-
ome project, which utilized lymphoblastoid cell lines as
source of DNA [8]. This difference could be caused by the
difference between the sources of biological material:
PMBCs versus cell lines. In cell line transformation, only a
small proportion of original cells are induced, hence the
heteroplasmy identified in a cell line only represents the
Table 4 Correlation of age with mtDNA heteroplasmy number
and copy number, adjusting for WBC and platelet counts
Parameter Parameter Estimate SE P Value
mtDNA heteroplasmy number 0.901 0.252 0.00037 ***
mtDNA copy number −0.013 0.004 0.00122 **
White blood cell count −0.301 0.176 0.08787
Platelet count 0.009 0.005 0.08590
Significance level (* P < 0.05, ** P < 0.01 and *** P < 0.001)
Table 3 Correlation of age with mtDNA heteroplasmy number
and copy number
Parameter Parameter Estimate SE P Value
mtDNA heteroplasmy number 1.185 0.271 1.27e-5 ***
mtDNA copy number −0.010 0.004 0.0228 *
Significance level (* P < 0.05, ** P < 0.01 and *** P < 0.001)
Fig. 4 Association between mtDNA heteroplasmy number and copy
number. mtDNA copy number was significantly associated with the
total heteroplasmy number within an individual, adjusting for age
and mean nuclear sequencing coverage (β = −4.34, P = 0.007).
Individuals harboring higher numbers of heteroplasmies were more
likely to have low mtDNA copy number
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heteroplasmy pattern for a few cells instead of the whole
cell populations [26]. Because the cell line and PBMC
samples show big differences in mtDNA characteristics
(Additional file 1: Figure S1), our study reinforces the no-
tion that using DNA directly extracted from human sam-
ples is ideal for studying the impact of aging on mtDNA
heteroplasmy and copy number. It is also important to
point out that our analysis is limited to PBMCs, which are
a mixture of different cell types. Further investigation of
mtDNA characteristics in these different cell types and
their relationship with aging will enable a better under-
standing on how mtDNA changes during aging.
We observed that heteroplasmy was not distributed
uniformly across the mitochondrial genome, and several
regions had enriched heteroplasmy: 1. The control
region had the highest length normalized occurrence
frequency; 2. Mutations located in tRNA-Thr had high
occurrence frequency in both heteroplasmy and homo-
plasmy; 3. Notably, the normalized occurrence frequency
of heteroplasmy in the ND5 gene was significantly
higher than other protein coding genes, while the
frequency of homoplasmy in ND5 was comparable to
other genes. mtDNA mutations in the tRNA-Thr and
ND5 regions have been reported to be implicated in
diseases including Leigh syndrome, mitochondrial myop-
athy, Parkinson’s disease and thyroid cancer [36]. The
high occurrence of mtDNA heteroplasmy in those
regions may be a potential source of future diseases,
or could reflect an underlying prodromal disease state
that independently promotes the accumulation of
mtDNA defects.
Using CADD score as a measure of pathogenicity, we
observed higher pathogenic potential of mtDNA hetero-
plasmy compared to homoplasmy, although still lower than
disease-associated mutations. We further grouped hetero-
plasmies by their MAF, and found that heteroplasmies with
lower MAF were more pathogenic than the ones with
higher MAF, implying that the selective pressure on highly
pathogenic heteroplasmies could be stronger, which could
occur during germline selection, and hence reduce those
heteroplasmies to low frequency. Due to mitochondrial
threshold effects [47], highly-pathogenic heteroplasmies
can persist in healthy individuals at low frequency; however,
once they reach high frequency, they could potentially
contribute to mitochondrial dysfunction and further lead to
the onset and/or progression of various age-related
diseases, as previously suggested [48–50].
It has been proposed that patients with mitochondrial
diseases experience a monoclonal expansion of a single
deleterious mtDNA mutation (for example, 3243A > G),
whereas aging is associated with a mosaic of multiple
low-level mtDNA mutations accumulated during a
lifetime [51]. mtDNA is replicated throughout the lifetime
of an individual, independent of cell cycle. Both inherited
and de novo mutations that emerged early in life could
clonally expand to increase the heteroplasmy burden over
time in a sub-population of cells. Several studies have
reported that the amount of mtDNA mutation increases
with age in several human tissues, including muscle,
colon, putamen and heart [52–55]. Consistent with these
reports, we observed that the heteroplasmy burden was
elevated in older individuals. In the current sample, the
absolute heteroplasmy number increased by 58.5% in
individuals over 70-years (mean age 74.04) compared to
individuals under 40-years (mean age 30.12). Mean-
while there was a trend for an increasing proportion of
nonsynonymous heteroplasmy in older individuals.
Given that the individuals involved in this study were
generally healthy, it is possible that in aged individuals
with diseases, more pronounced increases of hetero-
plasmy burden and pathogenicity would be observed.
Future large-scale prospective studies should investigate
the relationship between mtDNA heteroplasmy, disease
status, and mortality.
Fig. 5 mtDNA copy number association with phenotypic traits. a mtDNA copy number was positively associated with serum bicarbonate
level (P = 4.46e-5). The reference range for bicarbonate level is 22–29 mmol/L (b) mtDNA copy number was negatively associated with WBC count
(P = 0.0006). The reference range for WBC count is 4.0–11.0 (×109/L). The blue lines represent linear regression lines in each case
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Besides mtDNA quality, mtDNA quantity has also
been suspected to be influenced by age. We estimated
mtDNA copy number using WGS data, and found that
mtDNA copy number was negatively correlated with
age. These age-related mtDNA copy number changes
were also reported in other studies. Wachsmuth et al.
suggested that mtDNA copy number decreased with age
in human muscle tissue [37] and Sahin et al. found a
similar decrease in mice and rats in myocardial, hepatic,
and hematopoietic cells [56, 57]. In measurements from
whole blood, which are potentially confounded by
several factors, Mengel-From et al. also reported a
decline of 5.4 copies per decade of life in individuals
above 48 years old [12].
However, no studies have investigated whether the
effects of age on the two mitochondrial characteristics
are independent, as it is possible that age can affect
mtDNA copy number through age-related heteroplasmy
changes or vice versa. In this study, we demonstrated
that age was independently associated with mtDNA copy
number and heteroplasmy. Furthermore, compared to
previous studies, we also included WBC count and
platelet count as covariates in the regression model to
adjust for potential bias caused by blood cell contamina-
tions. Mitochondrial biogenesis has been proposed as a
marker of many age-related health outcomes or even the
aging process itself [58]. Our results suggested that both
mtDNA heteroplasmy and copy number should be
included to establish this relationship. Mitochondrial
mutations that occur early in life can clonally expand to
cause mitochondrial dysfunction and further contribute
to aging through a number of potential mechanisms
including decreased oxidative capacity and energy pro-
duction capacity, but also nuclear signaling and tran-
scriptional dysregulation [59–63]. In addition, decreased
mtDNA copy number may also lead to decreased energy
production and/or decreased mitochondrial gene expres-
sion [57, 64]. Maintaining both mtDNA quality and
quantity together may help to counteract or slow down
the aging process.
Our data were also consistent with the idea that
mtDNA copy number and heteroplasmy can influence
each other. We observed a negative correlation between
mtDNA copy number and total number of heteroplas-
mies in an individual. In mitochondrial diseases, a
compensatory increase in mtDNA copy number via
mitochondrial biogenesis may effectively compensate for
heteroplasmic mtDNA mutations and mitochondrial
dysfunction [65–67]. Thus, the observed age-related
copy number decrease may result in a weaker copy num-
ber buffering effect during aging. In contrast, our results
suggest that mtDNA haplogroups and homoplasmic
variants were not strongly associated with mtDNA copy
number. Although haplogroup T2 has been reported to be
associated with higher mtDNA copy number [42], we did
not observe this association in our dataset. This may be
caused by different sample sizes for this specific
haplogroup. Our data had 177 individuals belonging to T2
while the conclusions in the previous study [42] only
included 12 individuals. Another study suggested that
haplogroup J had higher copy number compared to hap-
logroup H [68]. However, neither Wachsmuth et al. [37]
nor our data found this difference. It should be noted that
our dataset only included UK females of European
descent. To identify potential haplogroup-related effects
on mtDNA copy number, further studies are needed to
include a more ethnically-diverse range of populations,
with both men and women, and larger sample sizes.
These age-related mitochondrial changes, combined
with the fact that age is the main risk factor of many
diseases in the population [69], further directed us to
investigate mitochondrial associations with human
physiological traits. After controlling for age, we found
that serum bicarbonate level and WBC count were
significantly associated with mtDNA copy number. The
bicarbonate-carbon dioxide buffer system in blood can
influence the pH gradient across the inner membrane of
mitochondria, and thus may provide a link between
systemic acid-base balance and regulation of mitochon-
drial metabolism [70, 71]. It has also been reported that
reducing muscle hydrogen ion accumulation by sodium
bicarbonate during running training was associated with
greater improvements in both mitochondrial mass and
mitochondrial respiration in rat models [72]. Our result
was consistent with these reports and suggests a poten-
tial interplay between the bicarbonate buffer system and
mitochondrial biogenesis with aging.
WBC count is a well-established marker for inflamma-
tion [73, 74]. Its negative correlation with mtDNA copy
number indicated a potential change in mitochondrial bio-
genesis during the immune response. Decreased peripheral
blood mtDNA copy number is observed in various diseases
accompanied with inflammation, for example, COPD was
associated with decreased leukocyte mtDNA copy number
[75]. Decreased mtDNA copy number was also observed
to be significantly associated with adverse clinical out-
comes in peritoneal dialysis patients [76]. Mitochondria
play an important role in inflammatory signaling; con-
versely, inflammation may also damage mtDNA, promot-
ing a vicious inflammatory cycle [77]. However, because
WBCs are a mixture of different immune cells, a change in
the composition of different immune cells, or all immune
cell types undergo similar age-related changes in mtDNA
copy number, may both contribute to the decrease of
mtDNA copy number detected here. Further studies are
needed to elucidate this observation. The link to specific
pro- and anti-inflammatory biomarkers will also be im-
portant to resolve.
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Most heteroplasmic variants had very low frequency in
the population, which limited our ability to test for asso-
ciations. Inspired by studies on nuclear DNA rare
variants [78, 79], instead of evaluating single variants,
we aggregated heteroplasmic mutations across the
entire mitochondrial genome as a “heteroplasmy mutation
load”, and tested the association between this mutation
load and different healthy traits. By applying the SKAT
algorithm, we found that mtDNA heteroplasmy load
was significantly associated with blood ApoB level inde-
pendent of age. Mitochondria play a critical role in fatty
acid metabolism (eg, β-oxidation). Furthermore, ApoB
is the main structural surface protein found on all beta-
lipoproteins, which is important for lipid transporta-
tion. The ApoB level is predictive for atherosclerosis
[80], and the onset of obesity is usually accompanied by
overproduction of ApoB [81]. Our result suggests a
potential interaction between mitochondrial function
and ApoB metabolism. It has been reported that the
suppression of the PPARα signaling pathway would
result in disrupted mitochondrial integrity and upregu-
lated hepatic apoB gene expression at both the transcrip-
tional and translational level in liver [82], providing a
potential mechanism for how mitochondrial dysfunction
is connected with ApoB metabolism. Nonetheless, further
studies are needed to elucidate this connection.
One limitation of our study is that all participates were
female. Given sex differences in mtDNA copy number mea-
sured in whole blood [24, 25, 83], our findings may not be
representative for both men and women. In a study of
whole blood, mtDNA copy number was previously reported
to be associated with waist circumference and waist-hip ra-
tio, suggesting an association between mtDNA copy num-
ber and fat distribution and lipid metabolism [25]. In our
study, we did not observe these associations, which could
possibly be caused by sex differences, or by other confound-
ing factors (platelets, cell-free DNA, or other) in previous
studies compared to purified leukocytes in this study.
Conclusion
In conclusion, using WGS data from the UK10K project
TwinsUK cohort, we conducted, to date, the first study
addressing whether the age effects on mtDNA hetero-
plasmy and copy number are independent. Our analyses
reveal that mtDNA copy number is inversely correlated
with heteroplasmy number, and associated with serum bi-
carbonate level and WBC count. Moreover, heteroplasmy
load is associated with blood ApoB level, suggesting future
avenues for research aimed at understanding the role of
mitochondrial dysfunction in human aging. Mitochondria
play a central role in cellular energy metabolism and regu-
late a broad range of cellular activities, and alterations of
mtDNA sequence integrity and copy number have been
implicated in human disease. Therefore, it remains
promising to further investigate whether approaches to
maintain mtDNA copy number and manage the expan-
sion of mtDNA heteroplasmic mutations could help im-
prove health status, especially in the elderly.
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